Skip to main content
Log in

Pharmacological properties of five diclofenac metabolites identified in human plasma

  • Design and Development of Drugs
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Five metabolites of diclofenac sodium (Voltarol®) have been identified in human plasma. All five metabolites were more than 50 times less potent than diclofenac in inhibiting PGE2 production in zymosan-stimulated mouse macrophages and LTC4 synthesis was not inhibited in these cells. Anti-inflammatory activity (adjuvant arthritis and carragheenan-induced paw oedema in rats) and analgesic activity (phenyl-p-benzoquinone writhing, mouse) of the metabolites were at least 10 times lower when compared to diclofenac. There was a good correlation betweenin vitro PGE2 inhibition andin vivo activities for diclofenac and its metabolites indicating that inhibition of prostaglandin synthesis is a major mechanism responsible for their pharmacological actions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. A. P. Todd and E. M. Sorkin,Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs35, 244–285 (1988).

    PubMed  Google Scholar 

  2. H. Stierlin, J. W. Faigle, A. Sallmann, W. Kueng, J. W. Richter, H.-P. Kriemler, K. O. Alt and T. Winkler,Biotransformation of diclofenac sodium (Voltaren ®)in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica9, 601–610 (1979).

    PubMed  Google Scholar 

  3. H. Stierlin and J. W. Faigle,Biotransformation of diclofenac sodium (Voltaren ®)in animals and man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. Xenobiotica9, 611–621 (1979).

    PubMed  Google Scholar 

  4. P. H. Degen, W. Dieterle, W. Schneider, W. Theobald and U. Sinterhauf,Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. Xenobiotica18, 1449–1455 (1988).

    PubMed  Google Scholar 

  5. J. W. Faigle, I. Boettcher, J. Godbillon, H. P. Kriemler, E. Schlumpf, W. Schneider, A. Schweizer, H. Stierlin and T. Winkler,A new metabolite of diclofenac sodium in human plasma, Xenobiotica18, 1191–1197 (1988).

    PubMed  Google Scholar 

  6. R. Menasse, P. R. Hedwall, J. Kraetz, C. Pericin, L. Riesterer, A. Sallmann, R. Ziel and R. Jaques,Pharmacological properties of diclofenac sodium and its metabolites. Scand. J. Rheumatol.22, 5–16 (1978).

    Google Scholar 

  7. I. Wiesenberg-Boettcher, A. Schweizer, J. R. Green, K. Mueller, F. Maerki and J. Pfeilschifter,The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound. Drugs Expl. Clin. Res.XV, 501–509 (1989).

    Google Scholar 

  8. A. Schweizer, R. Brom and H. Scherrer,Combined automated writhing/motility test for testing analgesics. Agents and Actions23, 29–31 (1988).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiesenberg-Boettcher, I., Pfeilschifter, J., Schweizer, A. et al. Pharmacological properties of five diclofenac metabolites identified in human plasma. Agents and Actions 34, 135–137 (1991). https://doi.org/10.1007/BF01993259

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01993259

Keywords

Navigation